Johnson & Johnson
NYSE:JNJ
Johnson & Johnson
EPS (Diluted)
Johnson & Johnson
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$8
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$2
|
CAGR 3-Years
-3%
|
CAGR 5-Years
45%
|
CAGR 10-Years
7%
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$6
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Zoetis Inc
NYSE:ZTS
|
EPS (Diluted)
$5
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$11
|
CAGR 3-Years
24%
|
CAGR 5-Years
6%
|
CAGR 10-Years
18%
|
|
Johnson & Johnson
Glance View
Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.
See Also
What is Johnson & Johnson's EPS (Diluted)?
EPS (Diluted)
9
USD
Based on the financial report for Mar 30, 2025, Johnson & Johnson's EPS (Diluted) amounts to 9 USD.
What is Johnson & Johnson's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
5%
Over the last year, the EPS (Diluted) growth was -43%. The average annual EPS (Diluted) growth rates for Johnson & Johnson have been 7% over the past three years , 7% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet